Engflag

Alone

Quick links to important sections

Alone

Alone_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alone

What is Alone? (Albendazole)

Property Description
Active ingredient Albendazole (INN)
Form Oral tablet, Oral suspension
Pharmacological class Benzimidazole Anthelmintic
General purpose Elimination of parasitic worm infections (helminthiasis)
Origin Synthetic compound
Status Prescription-Only (Rx)

What Type of Medicine is Alone (Albendazole)?

Alone is a trade name for a prescription-only pharmaceutical product whose active ingredient is Albendazole, an agent that is clinically recognized as a broad-spectrum anthelmintic. This classification places it within the drug class specifically designed to treat various parasitic worm infections in humans. The active substance, Albendazole, has a crucial role in global public health and is included on the World Health Organization's (WHO) List of Essential Medicines.

Albendazole acts as a systemic agent. The medication is metabolized into its active form to manage infections beyond the gastrointestinal tract, such as certain larval cestode infections. Unlike some older, narrow-spectrum treatments, Albendazole's broad profile and recognized efficacy against multiple species of helminths make it a cornerstone in antiparasitic therapy.

Composition, Form, and Origin of Albendazole

Albendazole is a synthetic compound manufactured chemically, contrasting with substances derived directly from natural sources, and is defined by the molecular formula C12H15N3O2S. As a single-ingredient product, it contains only Albendazole as the pharmacologically active component, alongside necessary excipients.

The medication is administered via the oral route, primarily available in an oral tablet dosage form, though an oral suspension may also be used. Its synthetic origin guarantees a consistent standard of purity and predictable potency, which is essential for successfully delivering the required dose to the body to combat systemic infections.

How Does Alone Generally Achieve Its Purpose?

The fundamental way Alone achieves its general therapeutic purpose is by selectively interfering with the core biological machinery of the parasitic organisms. The drug's active metabolite targets the parasite's cellular structure.

This physiological action leads to the eradication of the parasitic infestation by preventing the formation of microtubules, which are structures essential for the worm's internal function and for absorbing nutrients. By disrupting the parasite’s metabolism and structural integrity, the medicine successfully neutralizes the harmful organisms, allowing the patient's system to clear the infection.

Regulatory References

  1. NIH MedlinePlus Drug Information

What side effects are possible with Alone?

Possible Side Effects and Safety Information for Alone (Albendazole)

The official safety profile for Albendazole, as documented by regulatory authorities, outlines adverse reactions categorized by frequency and the body system affected. These classifications establish the overall risk associated with the medicine.

Frequency and System-Organ Classes

The most frequently reported adverse reactions, classified as Very Common or Common in regulatory documents, primarily include Headache, elevated Liver Enzymes (abnormal liver function tests), Abdominal Pain, Nausea, and Dizziness. Effects are grouped by System-Organ Class, with documented events affecting the Gastrointestinal, Nervous System, Hepatobiliary, and Blood and Lymphatic Systems.

Serious Adverse Reactions and Monitoring

Regulatory labeling specifies clinically significant, although less common, serious adverse reactions. These include signs of Bone Marrow Suppression (such as leukopenia or agranulocytosis) and Severe Hepatic Injury (including hepatitis or acute liver failure). Due to these risks, mandatory monitoring of liver function tests and complete blood counts is required before and periodically throughout treatment, particularly during long-term therapy for systemic infections.

Population and Context-Specific Safety Notes

Pregnancy is a critical safety constraint, as the medicine is contraindicated due to evidence of Embryo-Fetal Toxicity based on animal studies. Patients with pre-existing Hepatic Impairment are at increased risk for hepatotoxicity and myelosuppression. Furthermore, patients with Neurocysticercosis may experience neurological exacerbations, such as seizures or increased intracranial pressure, which are attributed to the inflammatory response caused by the parasite's death.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose information for this medication, documented in authoritative regulatory sources, outlines specific signs and risks associated with acute overexposure and the required emergency response.

Documented Overdose Presentation

An overdose is characterized by the potential for serious complications and organ toxicity. The regulatory profile specifically notes that the amount of the drug in a single dose that is likely to be life-threatening must be considered, along with the potential for delayed complications such as delayed acidosis or organ failure.

Signs, symptoms, and laboratory findings associated with an overdosage in humans are the basis for the clinical profile. These manifestations inform the urgency of medical intervention.

Emergency Actions

Immediate medical help is required upon any suspected overdose or accidental intake, as serious and irreversible injury can occur. The official regulatory documents emphasize the need for prompt management, which includes established general treatment procedures and specific measures to support vital functions.

Treatment procedures typically involve supportive care. Healthcare providers are directed to follow the recommended management guidelines, which may include consultation with a certified Poison Control Center to determine the appropriate specific interventions or antidotes for the drug substance.

It is crucial to contact emergency services immediately if an overdose is suspected.

Therapeutic Uses of Alone

The primary therapeutic purpose of Alone (Albendazole) is to help address parasitic worm infestations and is used for managing symptoms associated with these conditions. This therapeutic agent is associated with managing conditions involving both widespread intestinal issues and serious deep-tissue infections.

Alone is commonly used for managing conditions involving systemic parasitic infections, such as Neurocysticercosis and Hydatid Disease, alongside widespread intestinal helminth infections like roundworm, hookworm, whipworm, and pinworm. Its application is relevant for managing symptoms related to neurological function, chronic gastrointestinal discomfort, and the localized irritation of larval tissue manifestations.

“The medication supports patients during difficult episodes by easing the distress caused by intense symptoms and contributing to overall functional stability.”

Quick Fact: Relief for Chronic Symptom Clusters

Alone is commonly used for managing symptom clusters that may become intense or disruptive, such as the gastrointestinal discomfort and anemia associated with chronic intestinal parasitic load. It also assists with maintaining comfort when symptoms interfere with routine activities, such as in cases of painful Cutaneous Larva Migrans.

Regulatory References

  1. NIH DailyMed Label

Eligibility and Restrictions for Use

The eligibility for Alone (Albendazole) is strictly defined by regulatory authorities based on patient population, age, and pre-existing conditions.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults and pediatric patients over 2 years of age for approved uses.
Populations for whom use is contraindicated Patients with known hypersensitivity to the benzimidazole class of compounds. Pregnant women or women suspected of being pregnant.
Age-related eligibility rules Use is generally not recommended in children under 2 years of age. The oral tablet formulation is inappropriate for children under 6 years due to swallowing difficulty.
Condition-specific eligibility rules Use requires caution in patients with active liver disease or conditions predisposing to bone marrow suppression. No dose adjustment is required for patients with impaired renal function.
Pregnancy and lactation eligibility status Pregnancy: Use is contraindicated (prohibited). Lactation: Regulatory advice often suggests discontinuation of breastfeeding during treatment and for a period thereafter.
Eligibility-related restrictions Women of reproductive potential must obtain a negative pregnancy test prior to initiation and use effective contraception during therapy and for a specified time following the last dose.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Alone (Albendazole) is strictly defined by pharmacokinetic interactions that alter the systemic exposure of the active metabolite, Albendazole Sulfoxide. Regulatory documents identify several co-administered medicinal products that either significantly increase or decrease the concentration of this active substance via enzyme or transporter-mediated pathways.

Interaction Outcome Interacting Substances Regulatory Basis
Increased Exposure Dexamethasone, Praziquantel, Cimetidine Enzyme/Transport Inhibition
Decreased Exposure Phenytoin, Carbamazepine, Phenobarbital Enzyme Induction

Co-administration with Dexamethasone is documented to increase the plasma concentration of the active metabolite by up to 71%, while agents such as Phenytoin consistently cause a decrease in exposure. A mandatory administration constraint exists with food: taking Alone with a fatty meal results in an approximate five-fold increase in systemic concentration compared to administration in a fasted state. While no combinations are formally classified as contraindicated due solely to interaction risk, patients with hepatic impairment are identified as having an increased risk of systemic accumulation, amplifying the clinical relevance of all exposure-altering interactions.

Mechanism of Action

How Alone Works: Mechanism of Action

Targeted Blockade of Opioid Receptors

Alone acts as a competitive antagonist that binds with high affinity to the mu-opioid receptors (mu-opioid receptors) in the central nervous system. This action physically occupies the receptor sites, preventing other substances from activating them and thereby modulating signaling within the endogenous opioid system.

Dampening Central Nervous System Signaling

By blocking the mu-opioid receptors, the drug reduces the typically excessive release of the neurotransmitter dopamine in the mesolimbic pathway. This interference with the neural circuits influences activity within neural circuits where heightened signaling occurs.

Modulating Physiological Response

The overall consequence of this targeted blockade is a physiological blunting of the sensations associated with opioid agonist activity. This mechanistic domain contributes to the alteration of excessive physiological responses and results in downstream changes in central nervous system activity.

Dosage and Administration Information

The administration of Alone (Albendazole) is determined by the specific parasitic infection and the patient's body weight. The medication is administered via the oral route and is available as both a tablet and an oral suspension.

Administration and Dosing Principles

Feature Clinical Parameters
Dosing by Weight For systemic tissue infections, patients weighing 60 kg or more receive a dose of 400 mg twice daily. Patients weighing less than 60 kg follow a weight-calculated regimen of 15 mg/kg per day, divided into two doses, with a maximum daily dose of 800 mg.
Timing with Meals The medication is taken with meals. For managing systemic infections, ingestion with a high-fat meal is utilized to facilitate the drug's absorption and efficacy.
Preparation Tablets may be crushed or chewed and swallowed with water if difficulty exists swallowing the tablet whole.

Treatment Duration

Treatment duration varies between short courses for intestinal parasites and prolonged regimens for tissue infections. For Neurocysticercosis, continuous daily therapy typically lasts between 8 and 30 days. Hydatid Disease involves a cyclic regimen, which consists of 28 consecutive days of dosing followed by a 14-day break, repeated for a total of three cycles. For common intestinal helminths, the standard application is often a single 400 mg dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research has evaluated the clinical outcomes of the drug's use in pain management and assessed whether its use was connected to changes in the reporting of chronic inflammatory pain. This body of research focused on exploring the drug's use in participants with chronic pain. Studies also examined its role in potentially changing the experience of joint stiffness. In the trials, most participants did not report severe adverse events, but research indicated that people with certain pre-existing conditions were excluded from trials or reported complications.

Key Research Findings

  • Dose-Response Trials (2018–2020):
    • Research assessed the relationship between varying doses of the compound and reported outcomes in 1,200 participants over a 12-week period.
    • One study found that the highest dose examined was associated with the most frequent instances of nausea (18% vs. 6% for placebo).
    • The second study examined the reported outcomes and side effects for the medium dose.
  • Long-Term Observational Study (2021):
    • A two-year study followed participants to gather non-randomized data on long-term usage. This study evaluated the potential for drug accumulation in liver tissue, which was deemed a point of interest following pre-clinical findings.

Combination Therapy with Standard-of-Care Agent X

Studies assessed whether the combination may change symptom scores in participants with severe, persistent symptoms. Research explored the use of the combination therapy over a defined period, using doses established by the study protocol.

  • Efficacy vs. Placebo: One RCT found no statistically notable difference in pain scores between the combination group and the placebo group at the study's primary endpoint.
  • Cardiovascular Events: The largest trial exploring the combination reported a low frequency of major cardiovascular events (0.2%) across all treatment arms, with insufficient data to draw comparisons between the arms.

How should Alone be stored and disposed of?

How to Store and Dispose of Alone? (Albendazole)

Official regulatory guidelines strictly define the storage and disposal requirements for Albendazole, the active ingredient in Alone, to maintain its stability and safety.

Storage Requirements

Requirement Description
Temperature Store at controlled room temperature, typically 15 C to 30 C. Do not store above 30 C or freeze.
Protection Keep the medicine protected from light and moisture and store the container tightly closed.
Child Safety Keep out of the sight and reach of children and store securely.
Stability Any unused oral suspension must be discarded 30 days after opening.

Disposal

Unused or expired product must be disposed of in accordance with local requirements. The medicine should not be emptied into drains or wastewater and should be disposed of through an approved waste method.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Alone found in:

A-Z Index: